Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing...

Related Keywords

United States ,Canada ,American ,Paul Limburg ,Cara Connelly ,Kevin Conroy ,Megan Jones ,Sciences Corp ,Sciences On Facebook ,Sciences On Twitter Exactsciences ,Nasdaq ,Exchange Commission ,Prnewswire Exact Sciences Corp ,Panel Reliably Detects Colorectal Cancer ,Genomic Health Inc ,Sciences Corporation ,Us Preventive Services Task ,Screening At Exact Sciences ,National Comprehensive Cancer Network ,American Cancer Society ,Multi Target Stool ,Reliably Detects Colorectal Cancer ,Advanced Precancerous Lesions ,Exact Sciences ,Mayo Clinic ,Chief Medical Officer ,Colorectal Cancer ,Screening Rates Among ,Daverage Risk ,Colorectal Cancer Screening ,Discrete Choice ,Prospective Trial ,Multi Target Hepatocellular Carcinoma Blood Test ,Screening At Risk Patients ,Multi Target Blood Test Can Improve ,Hepatocellular Carcinoma Surveillance Programs ,Modeling Based Virtual Trial ,Genomic Health ,Exact Science ,New England Journal ,Services Task Force ,Second Generation Cologuard ,Risk Factors ,Annual Report ,Quarterly Reports ,Key Statistics ,Accessed May ,Exact Sciences Corp ,